Veclam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veclam

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Tablet, Oral Suspension
Pharmacological class Macrolide Antibiotic
Common purpose Treating bacterial infections
Origin Semisynthetic

What Type of Medicine is Veclam (Clarithromycin)?

Veclam is a prescription-only medicine containing the active ingredient clarithromycin, which is classified as a semi-synthetic macrolide antibiotic. This designation places it within a class of drugs effective against infections caused by susceptible bacteria. The molecule, Clarithromycin, is derived from the older antibiotic erythromycin through a chemical modification, making it semi-synthetic. This modification improves the drug's stability in the gastrointestinal tract and its absorption when administered orally, a property that is clinically recognized for ensuring consistent systemic drug delivery.


Composition and Available Forms of Veclam

The core composition of Veclam features Clarithromycin as the single active substance, delivered in various forms for oral use. It is available as both immediate-release tablets and extended-release tablets, as well as granules for oral suspension. The drug's availability in a liquid suspension form is particularly important for ease of administration to the pediatric patient group. The oral route of administration allows the active drug to be absorbed into the bloodstream to target internal infection sites.


General Purpose: How Clarithromycin Combats Infection

The general purpose of Clarithromycin is to control the spread of infection by interrupting the bacteria's ability to grow and reproduce. Clarithromycin achieves this by acting as a protein synthesis inhibitor, binding to the bacteria's internal machinery to prevent the creation of essential structural and functional proteins. This mechanism of inhibiting protein synthesis is supported by pharmacological studies as being key to its efficacy against a wide range of susceptible pathogens. This action limits the population of invading pathogens, enabling the body's immune system to neutralize the remaining bacterial infection.

Regulatory References

  1. Macrolides - StatPearls - NCBI Bookshelf

What side effects are possible with Veclam?

Possible Side Effects and Safety Information

The official safety profile of Veclam (clarithromycin) defines potential adverse reactions by frequency and the organ system affected, as documented in government regulatory sources.

Frequency-Classified Adverse Reactions

Adverse effects are categorized using standard regulatory frequency tiers. Common reactions documented in official labels include diarrhea, abdominal pain, nausea, vomiting, dysgeusia (taste disturbance), and headache. Reactions classified as Uncommon include anxiety, dizziness, palpitations, and changes noted on the electrocardiogram (ECG), such as QT prolongation.

System-Organ-Class Groupings

Side effects are grouped by the regulatory bodies according to the physiological system they impact:

  • Gastrointestinal Disorders: These are the most frequent, encompassing diarrhea, vomiting, and abdominal pain.
  • Hepatobiliary Disorders: Effects such as abnormal liver function tests and cases of hepatitis and fatal hepatic failure are officially documented.
  • Cardiac Disorders: The label includes documentation of risks associated with QT prolongation and serious ventricular arrhythmias, including Torsades de pointes.

Documented Safety Constraints and Serious Risks

Regulatory documents explicitly highlight serious, clinically significant reactions. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome, and potentially life-threatening Pseudomembranous Colitis. The drug is formally contraindicated in patients with a history of QT prolongation, specific cardiac arrhythmias, and in those with severe hepatic failure combined with renal impairment.

Safety notes also indicate that certain risks, such as C. difficile-associated diarrhea, may occur long after treatment has been completed. This profile provides a neutral, probability-based understanding of the medicine's documented risks.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented overdose profile for Veclam (Clarithromycin), based strictly on government regulatory information.

Documented Overdose Manifestations

Acute overdose is primarily characterized by severe gastrointestinal effects, including abdominal pain, nausea, vomiting, and diarrhea. Regulatory sources also note transient hearing loss and abnormal taste (dysgeusia) in association with high exposures.

Severe Outcomes and Emergency Actions

Overdose may lead to life-threatening complications affecting the cardiovascular and hepatic systems. Officially documented severe outcomes include QT interval prolongation and ventricular arrhythmias (such as Torsades de Pointes), and severe hepatic dysfunction that may be fatal. Immediate medical attention is required upon observing signs of systemic toxicity, such as collapse, seizure, severe respiratory distress, or signs of hepatitis (e.g., jaundice).

Management and Monitoring

No specific antidote is known for Clarithromycin overdose. The mandated regulatory procedure is symptomatic and supportive treatment. Continuous cardiac monitoring is required due to the risk of arrhythmias. Patients with renal impairment or pre-existing hepatic disease are noted to be at increased risk for severe outcomes.

Therapeutic Uses of Veclam

What Veclam Treats: Main Uses and Benefits

Veclam's active ingredient, Clarithromycin, is used in situations involving certain distressing symptoms across a range of conditions presenting with systemic or localized discomfort caused by susceptible bacteria. It is applied across therapeutic domains where additional symptomatic support is needed.

This medicine is relevant for the management of infections of the ears, sinuses, throat, and skin, as well as lower respiratory tract infections, such as bronchitis and pneumonia. It plays a role in managing the bacteria Helicobacter pylori, which is linked to ulcers, and is also considered relevant for easing symptoms associated with acute or episodic changes from Mycobacterium avium complex (MAC) infection in specific patient populations.

This assistance contributes to easing the overall symptom burden when symptoms become more noticeable. It supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus overview of Clarithromycin

Eligibility and Restrictions for Use

The eligibility for Veclam (clarithromycin) is determined by strict rules set forth in regulatory documents, focusing on patient health status and age. Use is generally restricted to adults, adolescents, and children ge 6 months using appropriate formulations.

Contraindicated Populations

Veclam is strictly contraindicated for patients who meet the following criteria:

  • A known hypersensitivity to clarithromycin, erythromycin, or any other macrolide antibiotic.
  • A history of QT prolongation (acquired or congenital) or ventricular cardiac arrhythmia.
  • The combination of severe hepatic failure and renal impairment.
  • Use of specific concomitant medications (e.g., simvastatin, lovastatin, ergot alkaloids) is prohibited.

Age and Condition-Specific Limitations

Category Official Regulatory Status
Infants (< 6 months) Safety and effectiveness Not Established (use is Not Recommended).
Children (< 12 years) Tablet formulations are Not Recommended.
Renal Impairment Use is conditional; requires Dose Adjustment for moderate-to-severe impairment.
Pregnancy/Lactation Use is Not Recommended unless benefits outweigh risks; drug is Excreted into Human Breast Milk.

Eligibility is also restricted for patients with risk factors for QT prolongation, such as uncorrected hypokalemia or clinically relevant bradycardia.

What should I know about interactions with other medicines?

Veclam’s interaction profile is significantly structured by its role as an inhibitor of the CYP3A4 enzyme and the P-glycoprotein ( P-gp) transporter. Co-administration with numerous medicines that are primarily metabolized by these systems can lead to increased systemic exposure of the co-administered drug.

Contraindicated Combinations

The most restrictive interactions involve statins (HMG-CoA reductase inhibitors) that are extensively metabolized by CYP3A4, such as lovastatin and simvastatin; co-administration is contraindicated. Similarly, co-administration with ergot derivatives, specifically ergotamine or dihydroergotamine, is contraindicated due to the risk of ergot toxicity.

Required Monitoring and Dose Adjustments

Close monitoring or dose adjustment is required for co-administration with other medicines. For oral anticoagulants (e.g., warfarin), the INR must be frequently monitored, and the anticoagulant's dose may need adjustment. Concomitant use with quinidine or disopyramide is restricted and requires ECG monitoring due to the potential for QT interval prolongation. Colchicine also requires dose adjustments or monitoring due to its dependence on the CYP3A4 and P-gp pathways. Separately, drugs that require an acidic stomach pH for absorption may have their effectiveness reduced when co-administered with this medicine. Finally, medicines that induce CYP3A4 (e.g., rifampicin, phenytoin) can decrease the concentration of this medicine.

Mechanism of Action

How Veclam Works (Clarithromycin)

The action of Veclam is defined by three complementary mechanistic domains that modulate bacterial viability and host physiological responses.


Direct Inhibition of Bacterial Protein Synthesis

This mechanism targets the bacterial ribosome by binding specifically to the 50S subunit, physically blocking the peptide exit tunnel . This action arrests the process of protein elongation and prevents the translocation process. The functional consequence is the cessation of bacterial growth (bacteriostasis) by interrupting protein elongation, shifting the microbial population dynamics.


Immunomodulation and Local Pathway Suppression

Clarithromycin exerts effects that go beyond antimicrobial activity by acting as a modulator of host physiological responses. This domain involves the suppression of pro-inflammatory cytokines (e.g., IL-1beta) and the inhibition of proteins involved in mucus hypersecretion and bacterial biofilm formation. These actions modulate overactive inflammatory pathways and inhibit processes associated with tissue hyper-responsiveness and mucus secretion.


Synergy via Active Metabolite and Tissue Delivery

The mechanism is enhanced by its systemic properties, notably its metabolism into the active compound, 14-hydroxyclarithromycin, which works synergistically with the parent drug. Crucially, the drug exhibits superior tissue penetration and accumulation in phagocytes. This accumulation serves as a targeted delivery system, maintaining high concentrations of the active substance directly at the deep-seated sites of microbial interaction.

Dosage and Administration Information

How Veclam is Used

Veclam (Clarithromycin) is strictly administered via the oral route, available as immediate-release (IR) tablets, extended-release (ER) tablets, and granules for oral suspension. The administration regimen, including dosage and frequency, is based on the specific type of bacterial infection being treated.


Administration Conditions and Frequency

Instruction Type Administration Principle
Route of Administration Oral route only for all available formulations.
IR Tablets and Suspension May be taken with or without food.
ER Tablets Must be taken with food to ensure proper absorption; must not be crushed, broken, or chewed.
Standard Adult Frequency Twice daily (every 12 hours) for IR forms; Once daily (every 24 hours) for ER forms.
Duration of Use Typically 7 to 14 days for most acute infections; long-term use is applied for Mycobacterium avium complex (MAC) infections.

Dosing and Population Adjustments

Standard adult dosing for the IR formulation is 250 mg to 500 mg per dose, while the ER dose is typically 1000 mg (1 g) once daily. Pediatric dosing for the oral suspension is weight-based (15 mg/kg/day) and divided every 12 hours. A mandatory adjustment exists for adults with severe kidney impairment (creatinine clearance less than 30 mL/min), for whom the total dose must be reduced by 50%. If a dose is missed, it is recommended to take it as soon as remembered, but skipping it if the next dose is due soon, strictly prohibiting doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Veclam

Evidence for Use in Respiratory Tract Infections

Research on the use of Veclam (clarithromycin) for infections like pneumonia and bronchitis has been conducted using short-term Randomized Controlled Trials (RCTs) and observational cohort studies. These studies were used in research exploring how symptoms change over time by measuring outcomes such as changes in physical discomfort (like fever and cough) and measurements of the specific bacteria's presence or absence. The populations observed included adults and adolescents, as well as children using the oral suspension form.

Research examined the patterns of symptom change in the observed populations during the study period. Studies report patterns related to the presence or absence of the targeted bacteria at the end of the treatment period. However, certain large-scale observational studies have monitored patients for years after treatment, and data show patterns related to non-infectious outcomes, particularly involving the heart. Because findings were mixed and inconsistent across these types of long-term studies, certainty remains low, and this area remains a focus of scientific consideration.


Evidence for Use in Treating Infections Related to H. pylori

Controlled Trials were conducted to evaluate combination treatments that include Veclam for conditions involving H. pylori bacteria, which can be associated with ulcers. The main outcome monitored was the H. pylori eradication rate, measured several weeks after treatment was complete.

Studies report the measured rates of bacterial presence or absence when the combination treatment was used. Findings indicate that these rates may vary depending on the specific combination of drugs used and the region where the study took place. Because research on the effectiveness of the drug is sensitive to regional resistance levels, data for certain groups remain insufficient.


What is Still Uncertain About Veclam Research

Scientific and regulatory research highlights what is known—and what is still uncertain regarding the studies conducted. Several limitations apply to the overall evidence landscape:

  • Antimicrobial Resistance: Efficacy is highly dependent on the local bacterial susceptibility patterns, meaning results do not determine whether an individual's infection will respond similarly in regions with known high resistance.
  • Long-Term Outcomes: There is limited information for long-term outcomes regarding the general use of the drug, particularly for non-infectious outcomes due to the mixed nature of the available follow-up data.
  • Special Subgroups: Subgroup findings are uncertain or limited for certain specific populations, such as pregnant populations, as these groups were often only lightly represented in the initial trials.

Key Studies & References

  1. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (Supports use in MAC infections, multi-drug regimens, and highlights drug-specific tolerance issues)
  2. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs | NIH - Clinical Info (Confirms clarithromycin as an agent in MAC primary prophylaxis and treatment regimens for immunocompromised patients)
  3. Clinical experience with clarithromycin for the treatment of respiratory tract infections (Covers RCTs against comparator drugs for pneumonia and bronchitis, including pediatric use)

Frequently Asked Questions (FAQ)

Common questions about Veclam (FAQ)

Q: What is Veclam used for besides the main thing listed on the website?

Regulatory documents state that Veclam (clarithromycin) is used for a variety of bacterial infections, including those affecting the respiratory tract (like certain pneumonias or sinusitis) and the skin and soft tissues. It is also indicated for the treatment of Mycobacterium avium complex (MAC) infection and in specific combination therapies for H. pylori infections that can be associated with duodenal ulcers.

Q: Can Veclam treat a fungal infection?

Veclam is classified as an antibiotic, meaning its purpose is to fight infections caused by susceptible bacteria. Its purpose is generally defined as treating infections caused by susceptible bacteria, and it is not intended for the treatment of viral or fungal infections.

Q: How quickly does Veclam start working after I begin taking it?

For most common infections, evidence indicates that patients may notice an improvement in symptoms within a few days of starting treatment. However, the exact time it takes for symptoms to resolve completely depends on the type of infection being treated and the individual's condition. The duration of the prescribed course of treatment is intended to ensure complete resolution of the infection.

Q: How long does Veclam stay in your system after you finish the full course?

Official pharmacological data indicates that the active drug is gradually cleared from the body. The elimination half-life of clarithromycin is typically between 3 and 7 hours, depending on the dosage. This suggests the active substance is generally eliminated over a period of a few days once the final dose has been taken.

Q: Can Veclam cause trouble sleeping?

Yes, regulatory safety reports have included 'trouble sleeping,' medically referred to as insomnia, as an adverse reaction. While this is noted in documentation, the precise frequency or likelihood of this reaction is not definitively classified in major regulatory documents.

Q: What common over-the-counter pain relievers should not be taken with Veclam?

Official drug labels focus on interactions with prescription medicines and specific enzyme systems, and they do not generally list specific common over-the-counter pain relievers as contraindications. Individuals should discuss all medications, including OTC pain relievers, with a healthcare provider to ensure there are no unlisted risks.

Q: Can Veclam interact with vitamins or herbal supplements?

Official product information indicates that Veclam interacts with drugs that affect the CYP3A4 enzyme in the liver, which includes certain herbal supplements like St. John's wort. Patients should notify their healthcare provider about all supplements, including vitamins, as some may require monitoring due to a possible interaction risk.

Q: Is Veclam safe for use by older adults (e.g., people over 65)?

Official documents note that the geriatric population may be more susceptible to certain drug-associated effects, particularly those involving the QT interval (a heart rhythm concern). Because of this, official documents note that this population may be more susceptible to certain heart rhythm effects and that monitoring may be necessary.

Q: Why is the full course of Veclam treatment so important?

Completing the entire prescribed course of treatment is important to ensure that the infection is thoroughly eliminated from the body. Stopping the medicine early, even if symptoms improve, increases the chance that some bacteria survive and potentially promotes the development of antibiotic resistance.

Q: Does Veclam change the effectiveness of birth control pills?

Official data indicates that clarithromycin may interact with some hormonal contraceptives, particularly those containing ethinyl estradiol. This interaction may potentially reduce the effectiveness of birth control pills. Official product information notes that alternative or additional methods of birth control may be discussed with a healthcare provider.

Q: Why do official documents mention potential hearing changes with Veclam?

Adverse reaction reports include mentions of hearing loss, tinnitus (a continuing ringing or buzzing sound in the ears), and vertigo (a sensation of spinning). These are documented in official safety information, but the frequency is not clearly defined or classified in major regulatory documents.

Q: Is the Veclam name recognized in all countries or is it marketed differently?

Veclam is one of the many brand names under which the active ingredient, clarithromycin, is sold. Official international drug databases confirm that clarithromycin is marketed globally under numerous different brand names.

Q: Can I take Veclam if I have a history of C. difficile infection?

Clarithromycin has been associated with Clostridium difficile-associated diarrhea (CDAD), which is a serious risk. Regulatory warnings indicate that a history of C. difficile-associated diarrhea (CDAD) is relevant to the use of clarithromycin, as CDAD has been reported with its use and can occur long after treatment is stopped.

Q: How does Veclam affect the 'good' bacteria in the gut?

Like other antibiotics, clarithromycin can impact the gut microbiota (the 'good' bacteria in the digestive system). Studies have shown that it can cause changes in the diversity of gut bacteria, including reduced levels of beneficial species such as Bifidobacterium and Lactobacillus.

Q: Do I need to avoid certain types of fruit or juice when using Veclam?

Some official data suggests that grapefruit juice might affect the rate at which clarithromycin is absorbed, but this effect is generally considered unlikely to be clinically significant. Official product information does not generally list mandatory fruit or juice restrictions.

Q: Can Veclam be used by people with a known allergy to penicillin?

Yes, Veclam (clarithromycin) belongs to a different class of antibiotics (macrolides) than penicillin. Because of this, it is often used as an alternative for patients who have a known allergy to penicillin.

Q: Why do I need a prescription for Veclam?

Veclam is classified as a prescription-only medicine by regulatory bodies. This requirement is in place due to the need for a professional medical diagnosis, the risk of serious side effects (like heart rhythm issues), and the necessity of appropriate use to manage the global risk of antibiotic resistance.

Q: Is it normal for my urine to change color while on Veclam?

Dark yellow or brown urine is a documented sign of liver injury, which is a serious, though uncommon, adverse reaction associated with clarithromycin use. Such an occurrence is documented as a potential sign of liver injury, and this information should be relayed to a healthcare professional.

Q: What happens if you have an overdose of Veclam?

Official regulatory information on overdose indicates that symptoms may include gastrointestinal issues such as abdominal pain, vomiting, nausea, and diarrhea. In the event of an overdose, medical professionals should eliminate the unabsorbed drug and provide supportive measures.

Q: Is it true that Veclam is not recommended for people with myasthenia gravis?

Yes, official warnings indicate that the underlying condition of myasthenia gravis (a neuromuscular disease) has been reported to worsen during treatment with clarithromycin. Patients with this pre-existing condition should use the drug with caution.

Q: What is the difference between Veclam and other common macrolides?

Veclam is a semi-synthetic drug derived from erythromycin, which is an older macrolide. Official information notes that the chemical modification to create clarithromycin was intended to improve the drug's stability in the stomach and its overall absorption when taken by mouth.

Q: Do you get side effects right away with Veclam or do they start later?

The timing of side effects can vary. While some common side effects, especially gastrointestinal issues, may start soon after beginning treatment, regulatory warnings also note that serious effects like C. difficile-associated diarrhea can occur long after the treatment course has been completed.

Q: What are the main signs of an allergic reaction to Veclam?

Official documents cite hypersensitivity as a contraindication and highlight the risk of severe reactions like Severe Cutaneous Adverse Reactions (SCARs). The signs of a severe allergic reaction can include swelling of the face, tongue, or throat, difficulty breathing, and severe skin rashes.

Q: Are there any food restrictions mentioned in official documents when taking Veclam?

The drug label specifies whether to take the immediate-release (IR) or extended-release (ER) forms with food, but generally does not list specific food restrictions. Detailed guidance on consumption should be obtained from a healthcare provider.

Q: What if I have liver disease, can I still use Veclam?

Regulatory information indicates a strict contraindication (must not be used) for patients who have the combination of severe hepatic failure and renal (kidney) impairment. The documentation also notes that cases of hepatitis and fatal liver failure have been reported, making careful use necessary for anyone with existing liver issues.

Q: Is it possible to develop resistance to Veclam over time?

Yes, official research acknowledges the issue of antimicrobial resistance. Efficacy is dependent on the local bacterial susceptibility patterns, and the selection pressure from antibiotic use can lead to the development of bacterial resistance in a population or during a course of treatment.

Q: What kind of research has been done on Veclam lately?

Research has been conducted on the use of Veclam for respiratory tract infections and in combination therapy for H. pylori associated with ulcers. While studies have been conducted over time, regulatory reviews note that there remains limited information for long-term outcomes, particularly for non-infectious conditions.

Q: Is the effectiveness of Veclam reduced by certain health conditions?

Yes, official drug labels require that the dosage be reduced by 50% for adult patients with severe kidney impairment. This indicates that severe kidney conditions can reduce the body's ability to process the drug effectively, potentially requiring an adjustment to maintain efficacy and safety.

Q: Is there a maximum time length Veclam is generally prescribed for?

The typical duration of use is 7 to 14 days for most acute infections. Official information also applies the drug to long-term use when treating complex infections like Mycobacterium avium complex (MAC), but the maximum duration for this long-term use is not rigidly defined as a single number.

How should Veclam be stored and disposed of?

Official Storage and Disposal Requirements

Labeled Storage Temperature Requirements 20 C to 25 C (68 F to 77 F) for tablets; Below 25 C (77 F) for unmixed granules.
Light and Packaging Constraints Tablets must be protected from light and kept in the original, tightly closed container.
Stability After Reconstitution The mixed oral suspension must not be refrigerated and any unused portion must be discarded after 14 days.
Child-Protection Storage Keep all forms of the medicine out of the reach and sight of children.
Disposal Instructions Expired or unused medication must be thrown away following official FDA guidelines. This generally involves mixing the medicine with an undesirable substance, such as used coffee grounds or kitty litter, before placing it in a sealed bag for disposal in the household trash. Personal information must be removed from the container prior to discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Veclam found in:

A-Z Index: